The Établissement français du sang (EFS) has launched a targeted public awareness campaign this April to address a critical necessitate for plasma donations across France. While whole blood donations often dominate the public conversation around blood drives, the EFS is shifting focus toward the specific, life-saving properties of plasma—the amber-colored liquid component of blood that serves as the raw material for essential medications.
Plasma constitutes about 55% of total blood volume and is rich in proteins, antibodies, and clotting factors. Unlike whole blood, which is often used in emergency trauma or surgical settings, plasma is primarily processed into plasma-derived medicinal products (PDMPs). These therapies are indispensable for patients with rare genetic disorders, severe immune deficiencies, and those recovering from catastrophic burns.
As a physician, I have seen the profound impact of these derivatives. For a patient with a primary immunodeficiency, an infusion of intravenous immunoglobulin (IVIG)—derived from the pooled plasma of thousands of healthy donors—is not merely a treatment; it is the primary defense against life-threatening infections. The current push by the Établissement français du sang aims to stabilize the supply chain for these critical biologics to ensure no patient faces a shortage of these specialized therapies.
The Medical Necessity of Plasma-Derived Therapies
The urgency of the EFS campaign stems from the fact that plasma cannot be synthesized in a laboratory. It must be harvested from human donors. Once collected, the plasma undergoes rigorous viral inactivation and purification processes to extract specific proteins that target a variety of medical conditions.
Among the most critical applications are albumin infusions, used to treat shock and severe burns by maintaining oncotic pressure in the blood vessels, and clotting factor concentrates, which are the gold standard for treating hemophilia. Without a steady stream of plasma donors, the production of these medicines would stall, directly impacting the quality of life and survival rates for thousands of patients across the European healthcare system.
The EFS emphasizes that plasma donation is a distinct act of altruism. Because the process takes longer than a standard blood donation, the pool of regular plasma donors is smaller, making each individual contribution more significant to the overall medical infrastructure.
Understanding the Apheresis Process
Many potential donors are hesitant about plasma donation because they are unfamiliar with the procedure, which differs significantly from a standard blood draw. To collect plasma efficiently, the EFS utilizes a process called apheresis, specifically plasmapheresis.
During apheresis, blood is drawn from the donor and passed through a centrifuge machine. This machine spins the blood at high speeds to separate the plasma from the red blood cells, white blood cells, and platelets. The plasma is collected in a sterile bag, while the remaining cellular components are immediately returned to the donor’s arm.
This cycle continues for a longer duration than a whole blood donation—typically between 45 and 90 minutes. From a clinical perspective, this method is advantageous because it allows the donor to recover their red blood cell mass almost instantly, meaning plasma donors can often give more frequently than those donating whole blood.
To help prospective donors understand the differences between these two types of contributions, the following table outlines the key distinctions:
| Feature | Whole Blood Donation | Plasma Donation (Apheresis) |
|---|---|---|
| Collection Time | Approximately 10–15 minutes | Approximately 45–90 minutes |
| What is Taken | All blood components | Only the liquid plasma |
| Recovery | Red cells take weeks to replace | Cellular components returned immediately |
| Frequency | Less frequent (8-12 weeks) | More frequent (every few weeks) |
Addressing the Donor Gap and Eligibility
Despite the high demand, plasma donation often suffers from lower visibility than whole blood drives. The EFS campaign seeks to bridge this gap by educating the public on who can donate and why the time commitment is worth the effort. To maintain the safety and efficacy of the resulting medicinal products, the EFS adheres to strict eligibility criteria.
Generally, healthy adults who meet the weight and age requirements for blood donation are eligible for plasma donation. However, because the process is more taxing on the circulatory system due to the duration of the procedure, donors must be in good general health and free from certain acute infections. The World Health Organization and national health bodies emphasize the importance of voluntary, non-remunerated donation to ensure the highest safety standards and the most ethical supply of blood products.
The EFS encourages potential donors to employ their digital platforms to schedule appointments, reducing wait times and optimizing the flow of donors through collection centers. This digital integration is part of a broader effort to modernize the French blood supply chain and make the act of giving more accessible to a younger, tech-savvy demographic.
Disclaimer: This article is provided for informational purposes only and does not constitute medical advice. Please consult with a healthcare provider or the EFS to determine your eligibility for blood or plasma donation.
The EFS is expected to continue its outreach throughout the spring, with a focus on increasing the number of registered “regular” plasma donors to avoid seasonal dips in supply. The next phase of the campaign will likely involve expanded mobile collection units to reach rural areas where access to permanent centers is limited.
Do you have experience with plasma donation, or do you have questions about the process? Share your thoughts in the comments below or share this article to help raise awareness.
